| . | Univariate analysis . | HR . | 95% CI . |
|---|---|---|---|
| Patient age/year | 0.71 | 1.01 | 0.95–1.07 |
| Gender, female | 0.66 | 0.81 | 0.29–1.99 |
| BMI | 0.71 | 0.96 | 0.79–1.17 |
| Duration of HD | 0.28 | 0.98 | 0.94–1.02. |
| Duration of AF (/year) | 0.046 | 1.18 | 1.00–1.38 |
| Structural heart disease | 0.96 | 1.02 | 0.44–2.39 |
| Congestive heart failure | 0.94 | 1.04 | 0.30–2.92 |
| Hypertension | 0.49 | 0.72 | 0.30–1.90 |
| Diabetes | 0.77 | 1.19 | 0.34–3.25 |
| Stroke | 0.047 | 6.96 | 1.03–29.0 |
| CHADS2 score | 0.5 | 1.20 | 0.70–1.97 |
| Failed AADs | 0.0005 | 1.70 | 1.27–2.29 |
| Echocardiography | |||
| LAD (/10 mm increase) | 0.12 | 1.94 | 0.84–4.42 |
| LVD (/10 mm increase) | 0.72 | 0.86 | 0.37–1.91 |
| LVEF (per 10% increase) | 0.45 | 0.84 | 0.55–1.35 |
| . | Univariate analysis . | HR . | 95% CI . |
|---|---|---|---|
| Patient age/year | 0.71 | 1.01 | 0.95–1.07 |
| Gender, female | 0.66 | 0.81 | 0.29–1.99 |
| BMI | 0.71 | 0.96 | 0.79–1.17 |
| Duration of HD | 0.28 | 0.98 | 0.94–1.02. |
| Duration of AF (/year) | 0.046 | 1.18 | 1.00–1.38 |
| Structural heart disease | 0.96 | 1.02 | 0.44–2.39 |
| Congestive heart failure | 0.94 | 1.04 | 0.30–2.92 |
| Hypertension | 0.49 | 0.72 | 0.30–1.90 |
| Diabetes | 0.77 | 1.19 | 0.34–3.25 |
| Stroke | 0.047 | 6.96 | 1.03–29.0 |
| CHADS2 score | 0.5 | 1.20 | 0.70–1.97 |
| Failed AADs | 0.0005 | 1.70 | 1.27–2.29 |
| Echocardiography | |||
| LAD (/10 mm increase) | 0.12 | 1.94 | 0.84–4.42 |
| LVD (/10 mm increase) | 0.72 | 0.86 | 0.37–1.91 |
| LVEF (per 10% increase) | 0.45 | 0.84 | 0.55–1.35 |
AADs, antiarrhythmic drugs; AF, atrial fibrillation; BMI, body mass index; CI, confidential interval; HD, haemodialysis; HR, hazard ratio; LAD, left atrial dimension at end-systole; LVD, left ventricular dimension at end-diastole; LVEF, left ventricular ejection fraction.
| . | Univariate analysis . | HR . | 95% CI . |
|---|---|---|---|
| Patient age/year | 0.71 | 1.01 | 0.95–1.07 |
| Gender, female | 0.66 | 0.81 | 0.29–1.99 |
| BMI | 0.71 | 0.96 | 0.79–1.17 |
| Duration of HD | 0.28 | 0.98 | 0.94–1.02. |
| Duration of AF (/year) | 0.046 | 1.18 | 1.00–1.38 |
| Structural heart disease | 0.96 | 1.02 | 0.44–2.39 |
| Congestive heart failure | 0.94 | 1.04 | 0.30–2.92 |
| Hypertension | 0.49 | 0.72 | 0.30–1.90 |
| Diabetes | 0.77 | 1.19 | 0.34–3.25 |
| Stroke | 0.047 | 6.96 | 1.03–29.0 |
| CHADS2 score | 0.5 | 1.20 | 0.70–1.97 |
| Failed AADs | 0.0005 | 1.70 | 1.27–2.29 |
| Echocardiography | |||
| LAD (/10 mm increase) | 0.12 | 1.94 | 0.84–4.42 |
| LVD (/10 mm increase) | 0.72 | 0.86 | 0.37–1.91 |
| LVEF (per 10% increase) | 0.45 | 0.84 | 0.55–1.35 |
| . | Univariate analysis . | HR . | 95% CI . |
|---|---|---|---|
| Patient age/year | 0.71 | 1.01 | 0.95–1.07 |
| Gender, female | 0.66 | 0.81 | 0.29–1.99 |
| BMI | 0.71 | 0.96 | 0.79–1.17 |
| Duration of HD | 0.28 | 0.98 | 0.94–1.02. |
| Duration of AF (/year) | 0.046 | 1.18 | 1.00–1.38 |
| Structural heart disease | 0.96 | 1.02 | 0.44–2.39 |
| Congestive heart failure | 0.94 | 1.04 | 0.30–2.92 |
| Hypertension | 0.49 | 0.72 | 0.30–1.90 |
| Diabetes | 0.77 | 1.19 | 0.34–3.25 |
| Stroke | 0.047 | 6.96 | 1.03–29.0 |
| CHADS2 score | 0.5 | 1.20 | 0.70–1.97 |
| Failed AADs | 0.0005 | 1.70 | 1.27–2.29 |
| Echocardiography | |||
| LAD (/10 mm increase) | 0.12 | 1.94 | 0.84–4.42 |
| LVD (/10 mm increase) | 0.72 | 0.86 | 0.37–1.91 |
| LVEF (per 10% increase) | 0.45 | 0.84 | 0.55–1.35 |
AADs, antiarrhythmic drugs; AF, atrial fibrillation; BMI, body mass index; CI, confidential interval; HD, haemodialysis; HR, hazard ratio; LAD, left atrial dimension at end-systole; LVD, left ventricular dimension at end-diastole; LVEF, left ventricular ejection fraction.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
